Equities analysts expect Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) to post sales of $876.57 million for the current fiscal quarter, according to Zacks Investment Research. Nine analysts have issued estimates for Alexion Pharmaceuticals’ earnings. The lowest sales estimate is $847.72 million and the highest is $900.89 million. Alexion Pharmaceuticals posted sales of $831.00 million during the same quarter last year, which suggests a positive year over year growth rate of 5.5%. The firm is expected to report its next earnings results on Thursday, February 15th.
According to Zacks, analysts expect that Alexion Pharmaceuticals will report full-year sales of $876.57 million for the current year, with estimates ranging from $3.49 billion to $3.54 billion. For the next fiscal year, analysts forecast that the firm will post sales of $4.07 billion per share, with estimates ranging from $3.91 billion to $4.28 billion. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that follow Alexion Pharmaceuticals.
Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.44 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.32 by $0.12. Alexion Pharmaceuticals had a return on equity of 12.55% and a net margin of 14.57%. The firm had revenue of $859.00 million during the quarter, compared to analyst estimates of $864.34 million. During the same period last year, the company posted $1.23 EPS. The business’s quarterly revenue was up 7.5% on a year-over-year basis.
ALXN has been the subject of a number of research analyst reports. JPMorgan Chase & Co. raised Alexion Pharmaceuticals from a “neutral” rating to an “overweight” rating and boosted their target price for the company from $163.00 to $175.00 in a research report on Tuesday, September 5th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $173.00 target price (up from $168.00) on shares of Alexion Pharmaceuticals in a research report on Wednesday, September 13th. SunTrust Banks reaffirmed a “buy” rating and issued a $180.00 target price (up from $170.00) on shares of Alexion Pharmaceuticals in a research report on Wednesday, September 13th. Leerink Swann reaffirmed an “outperform” rating and issued a $182.00 target price (up from $170.00) on shares of Alexion Pharmaceuticals in a research report on Wednesday, September 13th. They noted that the move was a valuation call. Finally, Deutsche Bank reiterated a “buy” rating and set a $158.00 price target (up previously from $153.00) on shares of Alexion Pharmaceuticals in a research note on Wednesday, September 13th. One research analyst has rated the stock with a sell rating, three have given a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $155.70.
Large investors have recently bought and sold shares of the stock. Fiduciary Trust Co. bought a new stake in Alexion Pharmaceuticals during the 2nd quarter valued at $111,000. Valeo Financial Advisors LLC bought a new stake in Alexion Pharmaceuticals during the 3rd quarter valued at $147,000. Dupont Capital Management Corp bought a new stake in Alexion Pharmaceuticals during the 3rd quarter valued at $156,000. BT Investment Management Ltd bought a new stake in Alexion Pharmaceuticals during the 3rd quarter valued at $165,000. Finally, YorkBridge Wealth Partners LLC raised its holdings in Alexion Pharmaceuticals by 221.7% during the 2nd quarter. YorkBridge Wealth Partners LLC now owns 1,425 shares of the biopharmaceutical company’s stock valued at $173,000 after acquiring an additional 982 shares during the period. 94.26% of the stock is currently owned by institutional investors.
Shares of Alexion Pharmaceuticals (NASDAQ ALXN) traded down $0.67 during trading on Friday, reaching $119.59. The company had a trading volume of 1,082,217 shares, compared to its average volume of 1,989,982. Alexion Pharmaceuticals has a twelve month low of $96.18 and a twelve month high of $149.34. The company has a market cap of $26,867.24, a price-to-earnings ratio of 53.39, a price-to-earnings-growth ratio of 1.31 and a beta of 1.18. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.96 and a quick ratio of 2.51.
ILLEGAL ACTIVITY WARNING: This piece was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another publication, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2018/01/14/876-57-million-in-sales-expected-for-alexion-pharmaceuticals-inc-alxn-this-quarter.html.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Get a free copy of the Zacks research report on Alexion Pharmaceuticals (ALXN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.